Skip to main content
    A

    Ardelyx Inc (ARDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.02 (-0.65%)

    Market Cap: $776.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ardelyx Inc (ARDX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Ardelyx are Adlai Nortye Ltd. American Depositary Shares (ANL), Avalo Therapeutics (AVTX) and ARS Pharmaceuticals (SPRY). By market cap, Ardelyx ranks 7th of the 13 companies on this page; Ultragenyx (RARE) is the largest at $1.64B.

    Peer Comparison

    ARDX's ROIC of -6.5% is above the peer median of -65.0%, and its revenue growth of 15.7% is above the median of 4.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Ardelyx (ARDX)$776.74MN/A1.6x-11.8%-6.5%15.7%0.00%
    Adlai Nortye Ltd. American Depositary Shares (ANL)$683.26MN/A8.1x-124.8%-7.3%178.1%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    ARS Pharmaceuticals, Inc (SPRY)$391.06MN/A2.9x-163.6%-143.8%16.0%0.00%
    Syndax Pharmaceuticals Inc (SNDX)$850.77MN/A2.8x-72.3%-65.0%81.6%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Janux Therapeutics Inc (JANX)$695.65MN/A29.6x0.0%N/A-7.1%0.00%
    Annexon Inc (ANNX)$747.79MN/AN/A0.0%-84.6%0.0%0.00%
    Mineralys Therapeutics, Inc. Common Stock (MLYS)$1.36BN/AN/A0.0%-51.1%0.0%0.00%
    Verastem Inc (VSTM)$1.03BN/A7.8x-178.4%-110.4%113.6%0.00%
    4D Molecular Therapeutics Inc (FDMT)$689.52MN/A8.5x-208.6%-46.4%4506.0%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Peer median$781.25M95.1x7.9x-35.9%-65.0%4.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Ardelyx, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Adlai Nortye Ltd. American Depositary Shares (ANL)
    Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    ARS Pharmaceuticals, Inc (SPRY)
    ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe...
    SPRY competitors
    Syndax Pharmaceuticals Inc (SNDX)
    Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
    SNDX competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Janux Therapeutics Inc (JANX)
    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology...
    JANX competitors
    Annexon Inc (ANNX)
    Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases.
    ANNX competitors
    Mineralys Therapeutics, Inc. Common Stock (MLYS)
    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular...
    MLYS competitors
    Verastem Inc (VSTM)
    Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients.
    VSTM competitors
    4D Molecular Therapeutics Inc (FDMT)
    4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors.
    FDMT competitors
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors

    Frequently Asked Questions About ARDX

    Who are Ardelyx's main competitors?

    The companies most similar to Ardelyx include Adlai Nortye Ltd. American Depositary Shares (ANL), Avalo Therapeutics (AVTX), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX) and Theravance Biopharma (TBPH), listed from the closest match.

    Who is Ardelyx's biggest competitor?

    Ultragenyx (RARE) is the largest of the similar companies at $1.64B; Adlai Nortye Ltd. American Depositary Shares (ANL) is the closest match by business profile, size, sector and industry.

    How does ARDX stock compare with its competitors?

    ARDX's P/S is 1.6x against a peer median of 7.9x; its net margin is -11.8% against a peer median of -35.9%.

    Which of Ardelyx's competitors pays a higher dividend?

    Ardelyx pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Ardelyx bigger than its competitors?

    No. Ardelyx is 7th by market cap among the 13 companies on this page; the largest is Ultragenyx (RARE) at $1.64B.